Dianthus initiated with a Buy at Truist

Truist analyst Danielle Brill initiated coverage of Dianthus (DNTH) with a Buy rating and $56 price target The recent Phase 2 proof-of-concept results with claseprubart in generalized myasthenia gravis were overall supportive of the thesis that Dianthus’ differentiated approach to targeting the autoantibody mediated complement cascade may offer similar efficacy as available complement inhibitors, but with a cleaner safety profile, says the analyst, who also thinks the gMG data are relatively de-risking for the ongoing Phase 3 chronic inflammatory demyelinating polyneuropathy trial.